Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897951 | 1.00 | LPAR1 (0.39) | LPAR1GRNSORT1PPARAPPARG | |
| SCHEMBL6896657 | 0.86 | GRN (0.43) | LPAR1GRNSORT1PPARAPPARG | |
| SCHEMBL6896652 | 0.86 | GRN (0.43) | LPAR1GRNSORT1PPARAPPARG | |
| SCHEMBL6897519 | 0.85 | LPAR1 (0.41) | LPAR1MMEACE | |
| SCHEMBL6897525 | 0.85 | LPAR1 (0.41) | LPAR1MMEACE | |
| SCHEMBL27538252 | 0.85 | LPAR1 (0.50) | LPAR1MMP1MMP3MMEACE | |
| SCHEMBL6896981 | 0.85 | LPAR1 (0.50) | LPAR1MMP1MMP3MMEACE | |
| SCHEMBL6897868 | 0.85 | LPAR1 (0.50) | LPAR1MMEACE | |
| SCHEMBL6896160 | 0.83 | LPAR1 (0.42) | LPAR1MMP1MMP3MME | |
| SCHEMBL27559916 | 0.83 | LPAR1 (0.42) | LPAR1MMP1MMP3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | LPAR1 4229/4885GRN 1445/4885SORT1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.